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Abstract
A 49-year-old woman developed an anaphylactic reaction to Tc-99m macrosalb used for pulmonary scintigraphy. The patient 
received an intravenous injection of Tc-99m macrosalb 120 MBq, containing macroaggregates of human albumin 0.14 mg. 
Within 1 min she developed itching all over her body, an itching throat and dyspnoea. This was followed by urticaria and 
facial oedema. She was diagnosed with an anaphylactic shock. The patient received clemastine and prednisone, and fully 
recovered after release from the hospital. According to the Naranjo assessment algorithm, the relationship between the 
allergic reaction and the administration of Tc-99m macrosalb should be considered as ‘probable’.
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Key Points 
Anaphylactic reactions to Tc-99m macrosalb may occur. 
Although rare, the possibility of such a reaction must be 
anticipated.
Healthcare professionals should check whether a patient 
has had a previous severe reaction to Tc-99m macrosalb.
Medical personnel should be prepared for these kinds of 
reactions, and suitable protocols for managing and treat-
ing anaphylactic reactions should be readily available.
Introduction
Tc-99m macrosalb (macro-aggregated albumin;  MAASOL®, 
the Netherlands) is a diagnostic radiopharmaceutical 
used in lung perfusion scans and venoscintigraphy. The 
radiopharmaceutical is reconstituted using a kit containing 
human serum albumin [1]. Single or multiple injections with 
Tc-99m macrosalb may be associated with chest pains, rigor 
and collapse. The frequency of adverse drug reactions in the use 
of radiopharmaceuticals in general is low, according to the lit-
erature. It is generally assumed that the frequency ranges from 
2.1 to 6 per 100,000 injections of radiopharmaceuticals [2, 3]. 
Although it includes a warning about the possibility of hyper-
sensitivity, according to the Summary of Product Characteris-
tics the frequency of hypersensitivity reactions is not known.
We report a case of a suspected severe Tc-99m mac-
rosalb-induced anaphylaxis. We also completed a litera-
ture search through PubMed and MEDLINE, without lan-
guage restrictions, applying no year limits and therefore 
extended as far back as the late 1940s. The search terminol-
ogy included both the following index terms and free-text 
words: ‘radiopharmaceutical’ or ‘radioisotope’ combined 
with ‘adverse effects’, ‘adverse reactions’, ‘adverse events’, 
or ‘side effects’. A filter for the search was applied to exclude 
animal-only studies. The search was completed in July 2018.
Only three case reports describing an adverse event fol-
lowing the administration of Tc-99m macrosalb were found 
but did not include an allergic reaction [4–6]. To the best 
of our knowledge, this is the first case report describing an 
anaphylactic reaction due to a Tc-99m macrosalb injection.
Case Presentation
A 49-year-old woman was referred for a lung perfusion 
scan because of possible chronic thromboembolic pul-
monary hypertension as a result of a previous pulmonary 
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embolism. The patient has a medical history of heterozy-
gosity for the prothrombin gene, Hemolysis Elevated Liver 
enzymes and Low Platelet count (HELLP) syndrome, as 
well as having had a stroke during pregnancy, mastitis, 
melanoma, pneumonia and pulmonary embolism. The 
concomitant medication used was rivaroxaban at 20 mg 
per day with a target international normalised ratio 
(INR) > 2.5 and oxycodone 5 mg when required for the 
relief of migraine attacks. As far as we know, the patient 
did not use over-the-counter products at the time of this 
adverse event.
With an estimated weight of 70  kg and height of 
160 cm, the patient received an intravenous (IV) injection 
of Tc-99m macrosalb 120 MBq, containing macroaggre-
gates of human albumin 0.14 mg, according to protocol. 
Within 1 min after the injection she developed itching all 
over the body, including an itching throat and dyspnoea. 
Subsequently, within a period of 5 min, urticaria emerged. 
Fifteen minutes after the administration of Tc-99m mac-
rosalb, the patient was transferred to the emergency room. 
Upon examination the patient had facial oedema, espe-
cially around the eyes. The left eye showed some redness 
and the patient still experienced slight dyspnoea. The 
emergency doctor diagnosed an anaphylactic reaction, 
without hemodynamic involvement. The patient was diag-
nosed with a type I allergic reaction. The patient received 
clemastine 2 mg IV and prednisone 25 mg IV. Approxi-
mately 2 or 3 h after administration of Tc-99m macrosalb, 
the symptoms improved. The patient was released from 
hospital upon recovery and was given clemastine 1 mg 
twice daily when required. She was contacted a few days 
later, and a full recovery was confirmed.
The patient had experienced a similar reaction, approxi-
mately 20 years ago, to a combination of acetaminophen, 
propyphenazone and caffeine  (Saridon®, Bayer B.V., the 
Netherlands), which was used to treat headache. Further-
more, she reported a similar reaction after an injection 
with a contrast medium used for a CT scan some years 
before the reaction to  Saridon®.
Discussion
To establish the frequency of adverse events following Tc-
99m macrosalb administration, we analyzed the number 
of doses dispensed (since 2011) at the Zwolle Radiophar-
macy versus reported adverse events. Our data showed 
that this was a single reported case of anaphylaxis in 6778 
doses dispensed for administration. This low frequency 
of adverse events is in line with what is described in the 
literature [7]. Furthermore, there are not many studies on 
this subject. Nevertheless, adverse events with radiophar-
maceuticals might be underreported [7, 8].
Several mammalian and avian serum albumins (SAs) 
are known allergens [9], and a rare case of an allergic 
reaction to technetium-labelled nanocolloidal albumin for 
sentinel node identification has been described [10], but 
not for Tc-99m macrosalb. Although no laboratory tests 
were sent off for confirmation and a clinical rechallenge 
was not carried out, it is most likely that the anaphylaxis 
was induced by Tc-99m macrosalb, as the symptoms arose 
immediately following the injection. For this particular 
patient we could not determine a prior exposure to Tc-
99m macrosalb, although this cannot be ruled out. None of 
the patient’s current medications could account for these 
hypersensitivity symptoms.
Table 1  Causality assessment of this case using the Naranjo algorithm [11]
No. Question Yes No Do not 
know
Score in this 
patient
1. Are there previous conclusive reports on this reaction? + 1 0 0 0
2. Did the adverse event appear after the suspected drug was administered? + 2 − 1 0 + 2
3. Did the adverse reaction improve when the drug was discontinued or a specific antagonist 
was administered?
+ 1 0 0 + 1
4. Did the adverse reaction reappear when the drug was readministered? + 2 − 1 0 0
5. Are there alternative causes (other than the drug) that could on their own have caused the 
reaction?
− 1 + 2 0 + 2
6. Did the reaction reappear when a placebo was given? − 1 + 1 0 0
7. Was the drug detected in the blood (or other fluids) in concentrations known to be toxic? + 1 0 0 0
8. Was the reaction more severe when the dose was increased, or less severe when the dose 
was decreased?
+ 1 0 0 0
9. Did the patient have a similar reaction to the same or similar drugs in any previous expo-
sure?
+ 1 0 0 0
10. Was the adverse event confirmed by any objective evidence? + 1 0 0 + 1
Total score 6
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The timing between administration of the drug and the 
start of the symptoms, as well as the fact that this adverse 
drug reaction is mentioned in the Summary of Product 
Characteristics (SmPC), is suggestive of a causal relation. 
We performed a causality assessment using the Naranjo 
algorithm. The Naranjo algorithm uses ten questions that 
are scored. The sum of the score gives an indication of 
probability [11]. The results—using this causality assess-
ment method—are presented in Table 1. A Naranjo assess-
ment score of 6 was obtained, indicating that the relation-
ship between the allergic reaction and the administration 
of Tc-99m macrosalb should be considered as ‘probable’. 
The outcome ‘probable’ was assigned since the allergic 
reaction reasonably correlated with time of onset of the 
reaction, improved after withdrawal of Tc-99m macrosalb 
and could not be ascribed to other characteristics of the 
patient.
The reaction could be caused by the active ingredi-
ent of Tc-99m macrosalb, namely macro-aggregates 
prepared from human serum albumin. Anaphylaxis has 
been described for human albumin used as volume substi-
tutes [12–14]. In one study, an incidence of 0.011% was 
determined [13]. However, the amount of human albumin 
administered as volume substitutes is general much higher 
(in the order of whole grams) than the amount of Tc-99m 
macrosalb given (a fraction of a milligram). It could also 
be the case be that one of the excipients of the formulation 
caused the reaction. As far as we know, the patient had not 
previously been exposed to Tc-99m macrosalb or to one 
to its excipients, which would have been required for any 
prior sensitisation. Whether or not the anaphylaxis was 
caused by an allergic reaction or a non-immune mediated 
reaction is therefore not clear.
Conclusion
Anaphylactoid reactions to Tc-99m macrosalb may occur. 
Although rare, the possibility of such a reaction must be 
anticipated. Healthcare professionals should check if a 
patient has had a previous severe reaction to Tc-99m mac-
rosalb. Medical personnel should be prepared for these kind 
of reactions, and suitable protocols for managing and treat-
ing anaphylactoid reactions should be readily available.
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